{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:57:24Z","timestamp":1753891044903,"version":"3.41.2"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020R1A3B3079653, 2020M3H1A1073304"],"award-info":[{"award-number":["NRF-2020R1A3B3079653, 2020M3H1A1073304"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In addition to SARS-CoV-2 and its variants, emerging viruses that cause respiratory viral infections will continue to arise. Increasing evidence suggests a delayed, possibly suppressed, type 1 interferon (IFN-I) response occurs early during COVID-19 and other viral respiratory infections such as SARS and MERS. These observations prompt considering IFN-\u03b2 as a prophylactic or early intervention for respiratory viral infections. A rationale for developing and testing intranasal interferon beta (IFN-\u03b2) as an immediately available intervention for new respiratory viral infections that will arise unexpectedly in the future is presented and supported by basic and clinical trial observations. IFN-\u03b2 prophylaxis could limit the spread and consequences of an emerging respiratory viral infection in at-risk individuals while specific vaccines are being developed.<\/jats:p>","DOI":"10.3389\/fimmu.2021.660298","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T06:08:19Z","timestamp":1621404499000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections"],"prefix":"10.3389","volume":"12","author":[{"given":"Amos C.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunjin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haewook","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunghoon","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Repine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A Novel Coronavirus Outbreak of Global Health Concern","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12879-020-05730-z","article-title":"JAK-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis","volume":"21","author":"Walz","year":"2021","journal-title":"BMC Inf Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6027","article-title":"Impaired Type I Interferon Activity and Inflammatory Responses in Severe COVID-19 Patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2012-0339OC","article-title":"Innate Immune Response of Human Alveolar Type II Cells Infected With Severe Acute Respiratory Syndrome-Coronavirus","volume":"48","author":"Qian","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-Cov-2 Receptor Ace2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets Across Tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa453","article-title":"Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early Covid-19","volume":"71","author":"O\u2019Brien","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01410-20","article-title":"Type I Interferon Susceptibility Distinguishes SARS-CoV-2 From SARS-Cov","volume":"94","author":"Lokugamage","year":"2020","journal-title":"J Virol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and Type Iii Interferons - Induction, Signaling, Evasion, and Application to Combat Covid-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6261","article-title":"Systems Biological Assessment of Immunity to Mild Versus Severe COVID-19 Infection in Humans","volume":"369","author":"Arunachalam","year":"2020","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02581-06","article-title":"Multiple Anti-Interferon Actions of the Influenza A Virus NS1 Protein","volume":"81","author":"Kochs","year":"2007","journal-title":"J Virol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cell.2020.08.028","article-title":"Effects of COVID-19 on the Nervous System","volume":"183","author":"Iadecola","year":"2020","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.11.20061473","article-title":"An Experimental Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in an Epidemic Area","author":"Meng","year":"2020","journal-title":"medRxiv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple Combination of Interferon beta-1b, Lopinavir\u2013Ritonavir, and Ribavirin in the Treatment of Patients Admitted to Hospital With COVID-19: An Open-Label, Randomised, Phase 2 Trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.05320-0","article-title":"Description and Clinical Treatment of an Early Outbreak of Severe Acute Respiratory Syndrome (SARS) in Guangzhou, Pr China","volume":"52","author":"Zhao","year":"2003","journal-title":"J Med Microbiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70920-X","article-title":"Ribavirin and Interferon alfa-2a for Severe Middle East Respiratory Syndrome Coronavirus Infection: A Retrospective Cohort Study","volume":"14","author":"Omrani","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4172\/2332-0877.1000223","article-title":"The Most Effective Therapeutic Regimen for Patients With Severe Middle East Respiratory Syndrome Coronavirus (Mers-CoV) Infection","volume":"3","author":"Al-Qaseer","year":"2015","journal-title":"J Infect Dis Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"396","DOI":"10.5144\/0256-4947.2014.396","article-title":"Middle Eastern Respiratory Syndrome Corona Virus (Mers CoV): Case Reports From a Tertiary Care Hospital in Saudi Arabia","volume":"34","author":"Khalid","year":"2014","journal-title":"Ann Saudi Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2013.12.003","article-title":"Ribavirin and Interferon Therapy in Patients Infected With the Middle East Respiratory Syndrome Coronavirus: An Observational Study","volume":"20","author":"Al-Tawfiq","year":"2014","journal-title":"Int J Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12879-016-1492-4","article-title":"Treatment Outcomes for Patients With Middle Eastern Respiratory Syndrome Coronavirus (Mers CoV) Infection At a Coronavirus Referral Center in the Kingdom of Saudi Arabia","volume":"16","author":"Al Ghamdi","year":"2016","journal-title":"BMC Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31101-6","article-title":"Interferon beta-1b for COVID-19","volume":"395","author":"Shalhoub","year":"2020","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.04325","article-title":"Acute Management and Long-Term Survival Among Subjects With Severe Middle East Respiratory Syndrome Coronavirus Pneumonia and ARDS","volume":"61","author":"Khalid","year":"2016","journal-title":"Respir Care"},{"key":"B24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3851\/IMP2792","article-title":"Ribavirin and Interferon-\u03b12b as Primary and Preventive Treatment for Middle East Respiratory Syndrome Coronavirus: A Preliminary Report of Two Cases","volume":"20","author":"Khalid","year":"2015","journal-title":"Antivir Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3002","article-title":"Combination Therapy With Lopinavir\/Ritonavir, Ribavirin and Interferon-a for Middle East Respiratory Syndrome","volume":"21","author":"Kim","year":"2016","journal-title":"Antivir Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3201\/eid2203.151049","article-title":"Middle East Respiratory Syndrome Coronavirus During Pregnancy, Abu Dhabi, United Arab Emirates, 2013","volume":"22","author":"Malik","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70226-1","article-title":"250 \u03bcg or 500 \u03bcg Interferon beta-1b Versus 20 Mg Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis: A Prospective, Randomised, Multicentre Study","volume":"8","author":"O\u2019Connor","year":"2009","journal-title":"Lancet Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1474-4422(11)70262-9","article-title":"Comparison of Two Dosing Frequencies of Subcutaneous Interferon beta-1a in Patients With a First Clinical Demyelinating Event Suggestive of Multiple Sclerosis (REFLEX): A Phase 3 Randomised Controlled Trial","volume":"11","author":"Comi","year":"2012","journal-title":"Lancet Neurol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular Interferon Beta-1a Therapy Initiated During a First Demyelinating Event in Multiple Sclerosis","volume":"343","author":"Jacobs","year":"2000","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.43.4.655","article-title":"Interferon beta-1b is Effective in Relapsing-Remitting Multiple Sclerosis. I. Clinical Results of a Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial","volume":"43","author":"Duquette","year":"1993","journal-title":"Neurology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000237641.33768.8d","article-title":"Treatment With Interferon beta-1b Delays Conversion to Clinically Definite and McDonald MS in Patients With Clinically Isolated Syndromes","volume":"67","author":"Kappos","year":"2006","journal-title":"Neurology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611337","article-title":"Mucosal Immunity in COVID-19: A Neglected But Critical Aspect of SARS-CoV-2 Infection","volume":"11","author":"Russell","year":"2020","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3897\/rio.6.e61709","article-title":"Ahead of a Vaccine: A Safe Method of Protection Against COVID-19 Exists","volume":"6","author":"Alibek","year":"2020","journal-title":"Res Ideas Outcomes"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/154.3.443","article-title":"Prevention of Experimental Coronavirus Colds With Intranasal -2b Interferon","volume":"154","author":"Turner","year":"1986","journal-title":"J Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02453-08","article-title":"Intranasal Administration of Alpha Interferon Reduces Seasonal Influenza A Virus Morbidity in Ferrets","volume":"83","author":"Kugel","year":"2009","journal-title":"J Virol"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1177\/135965350400900618","article-title":"Increased Sensitivity of SARS-coronavirus to a Combination of Human Type I and Type II Interferons","volume":"9","author":"Scagnolari","year":"2004","journal-title":"Antivir Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104811","article-title":"Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection","volume":"179","author":"Mantlo","year":"2020","journal-title":"Antiviral Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13973-6","article-title":"Treatment of SARS With Human Interferons","volume":"362","author":"Cinatl","year":"2003","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","article-title":"Safety and Efficacy of Inhaled Nebulised Interferon beta-1a (SNG001) for Treatment of SARS-CoV-2 Infection: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"9","author":"Monk","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.13719","article-title":"Presence of Genetic Variants Among Young Men With Severe Covid-19","volume":"324","author":"van der Made","year":"2020","journal-title":"JAMA"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2020.0214","article-title":"Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2","volume":"40","author":"Xia","year":"2020","journal-title":"J Interf Cytokine Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1177\/1756285612450936","article-title":"Current and Emerging Therapies in Multiple Sclerosis: A Systematic Review","volume":"5","author":"Castro-Borrero","year":"2012","journal-title":"Ther Adv Neurol Disord"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00065-21","article-title":"Considering Personalized Interferon Beta Therapy for COVID-19","volume":"65","author":"Dorgham","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30484-8","article-title":"Inclusion of Pregnant Women in COVID-19 Treatment Trials: A Review and Global Call to Action","volume":"9","author":"Taylor","year":"2020","journal-title":"Lancet Glob Heal"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-00731-9","article-title":"Interferons and Viruses Induce a Novel Truncated ACE2 Isoform and Not the Full-Length SARS-CoV-2 Receptor","volume":"52","author":"Onabajo","year":"2020","journal-title":"Nat Genet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","article-title":"SARS-Cov-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract","volume":"182","author":"Hou","year":"2020","journal-title":"Cell"},{"key":"B47","doi-asserted-by":"publisher","first-page":"019459982093317","DOI":"10.1177\/0194599820933170","article-title":"Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (Covid-19): A State of the Art Review","volume":"163","author":"Higgins","year":"2020","journal-title":"Otolaryngol Neck Surg"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01061","article-title":"Interferon-\u03b12b Treatment for COVID-19","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1055\/a-1170-4395","article-title":"Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen With Interferon Beta","volume":"70","author":"Brzoska","year":"2020","journal-title":"Drug Res (Stuttg)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096967","article-title":"Glycoengineering of Interferon-\u03b2 1a Improves its Biophysical and Pharmacokinetic Properties","volume":"9","author":"Song","year":"2014","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.chom.2020.04.017","article-title":"Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients","volume":"27","author":"Zhou","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41577-020-00429-3","article-title":"The Type I Interferon Response in COVID-19: Implications for Treatment","volume":"20","author":"Lee","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1126\/sciimmunol.abd1554","article-title":"Immunophenotyping of COVID-19 and Influenza Highlights the Role of Type I Interferons in Development of Severe COVID-19","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4585","article-title":"Auto-Antibodies Against Type I Ifns in Patients With Life-Threatening COVID-19","volume":"65","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.chom.2020.07.005","article-title":"Retrospective Multicenter Cohort Study Shows Early Interferon Therapy is Associated With Favorable Clinical Responses in COVID-19 Patients","volume":"28","author":"Wang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4857","article-title":"Covid-19: New Coronavirus Variant is Identified in UK","volume":"371","author":"Wise","year":"2020","journal-title":"BMJ"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.660298\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T21:36:35Z","timestamp":1672176995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.660298\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2021.660298"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.660298","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"article-number":"660298"}}